Nine awardees will split $12.7 million from the NIH to find new targets for eight abandoned drug compounds. Critics say the National Center for Advancing Translational Sciences program has low odds of succeeding because drugmakers that developed the compounds abandoned them for a reason. Proponents say even moderate success will yield substantial return on the investment.

Related Summaries